Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
Authors' conclusion
In addition to CMRF, MASLD and MetALD were associated with a higher incidence of thyroid cancer in the Korean population.
Study context
- Population
- Korean adults aged ≥40 years in the National Health Screening Program 2009–2010, without history of liver disease or malignancy
- Participants
- 214,502 adults
- Exposure
- Cardiometabolic risk factor (CMRF)/steatotic liver disease (SLD) categories vs no SLD without CMRF
- Outcome
- Diagnosis of new thyroid cancer during follow-up
- Follow-up
- Average 9.61 years
Methodological detailsnationwide, multivariable-adjusted Cox proportional hazards model
- Nationwide
- Multivariable-adjusted Cox proportional hazards model
Main finding
As reported in the abstract
Incident thyroid cancer
Each group vs no SLD without CMRFHazard ratio (CI)
No SLD with CMRF
1.33(1.16–1.52)
MASLD
1.36(1.17–1.58)
MetALD
1.40(1.04–1.88)
- Newly diagnosed thyroid cancer, overall
- 2761 (1.3%)
Observational data: associations, not effects.
Further findings
Thyroid cancer incidence by sex
- MetALD significantly associated with thyroid cancer incidence solely in men
Original publication
Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer. Thyroid. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →